Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.37 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | TP53 | P04637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228763 | 0.89 | S1PR1 (0.64) | S1PR1MAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL15966895 | 0.88 | S1PR1 (0.54) | S1PR1MAPK1HTTSMN1; SMN2NPC1 | |
| SCHEMBL14796985 | 0.84 | S1PR1 (0.57) | S1PR1POLBMAPK1HTTSMN1; SMN2 | |
| SCHEMBL2225593 | 0.80 | S1PR1 (0.52) | S1PR1POLBNPC1KDM4EALDH1A1 | |
| SCHEMBL2224650 | 0.78 | S1PR1 (0.58) | S1PR1MAPK1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14797011 | 0.78 | S1PR1 (0.82) | S1PR1MAPK1KDM4EALDH1A1HPGD | |
| SCHEMBL2223368 | 0.78 | S1PR1 (0.83) | S1PR1MAPK1KDM4EALDH1A1CYP1A2 | |
| SCHEMBL14797017 | 0.75 | S1PR1 (0.73) | S1PR1HTTKDM4EALDH1A1HPGD | |
| SCHEMBL2221025 | 0.75 | S1PR1 (0.83) | S1PR1POLBMAPK1HTTSMN1; SMN2 | |
| SCHEMBL2224775 | 0.74 | S1PR1 (0.48) | S1PR1SMN1; SMN2KDM4EALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | claimed |
| EP-2523963-B1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES AS EDG-1 AGONISTS | SANOFI SA (FR) | 2014-08-27 | — | — | EP | claimed |
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-03-21 | — | — | US | claimed |
| EP-2523963-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | claimed |
| WO-2011086081-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | claimed |
| US-9040544-B2 | 2,5-substituted oxazolopyrimidine derivatives | SANOFI (FR) | 2015-05-26 | — | — | US | disclosed |
| EP-2523963-B1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES AS EDG-1 AGONISTS | SANOFI SA (FR) | 2014-08-27 | — | — | EP | disclosed |
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2013-03-21 | — | — | US | disclosed |
| EP-2523963-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI (FR) | 2012-11-21 | — | — | EP | disclosed |
| WO-2011086081-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072501-A1 | 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE DERIVATIVES | DPYD, CDK2, CCNT2 | S1PR1 1027/4885POLB 386/4885MAPK1 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.